Delivery Devices Crucial To Success, Lifespan Of Asthma/COPD Meds
This article was originally published in The Gray Sheet
Executive Summary
Sales of Merck’s Singulair fell off the molecular patent cliff, but not Glaxo’s still-mighty Advair. Why? Because it has an additional patent protecting its delivery device.
You may also be interested in...
Advair Generics Likely Lucrative Product For Few That Can Clear High Bar
With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.
Merck & Co. Files First IRA Suit, Signaling Industry Is Ready To Fight
Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.